Literature DB >> 19710144

Identification of amino acid residues critical for the anti-interferon activity of the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus.

Luis Martínez-Sobrido1, Sébastien Emonet, Panagiotis Giannakas, Beatrice Cubitt, Adolfo García-Sastre, Juan C de la Torre.   

Abstract

Lymphocytic choriomeningitis virus (LCVM) nucleoprotein (NP) counteracts the host type I interferon (IFN) response by inhibiting activation of the IFN regulatory factor 3 (IRF3). In this study, we have mapped the regions and specific amino acid residues within NP involved in its anti-IFN activity. We identified a region spanning residues 382 to 386 as playing a critical role in the IFN-counteracting activity of NP. Alanine substitutions at several positions within this region resulted in NP mutants that lacked the IFN-counteracting activity but retained their functions in virus RNA synthesis and assembly of infectious particles. We used reverse genetics to rescue a recombinant LCMV strain carrying mutation D382A in its NP [rLCMV/NP*(D382A)]. Compared to wild-type (WT) LCMV, rLCMV/NP*(D382A) exhibited a higher level of attenuation in IFN-competent than IFN-deficient cells. In addition, A549 cells infected with rLCMV/NP*(D382A), but not with WT LCMV, produced IFN and failed to rescue replication of the IFN-sensitive Newcastle disease virus.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19710144      PMCID: PMC2772779          DOI: 10.1128/JVI.00763-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  Identification of the lymphocytic choriomeningitis virus (LCMV) proteins required to rescue LCMV RNA analogs into LCMV-like particles.

Authors:  Ki Jeong Lee; Mar Perez; Daniel D Pinschewer; Juan Carlos de la Torre
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

2.  A recombinant influenza A virus expressing an RNA-binding-defective NS1 protein induces high levels of beta interferon and is attenuated in mice.

Authors:  Nicola R Donelan; Christopher F Basler; Adolfo García-Sastre
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

3.  The small RING finger protein Z drives arenavirus budding: implications for antiviral strategies.

Authors:  Mar Perez; Rebecca C Craven; Juan C de la Torre
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-16       Impact factor: 11.205

4.  A C-terminal basic amino acid motif of Zaire ebolavirus VP35 is essential for type I interferon antagonism and displays high identity with the RNA-binding domain of another interferon antagonist, the NS1 protein of influenza A virus.

Authors:  Amy L Hartman; Jonathan S Towner; Stuart T Nichol
Journal:  Virology       Date:  2004-10-25       Impact factor: 3.616

5.  Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease.

Authors:  Eileen Foy; Kui Li; Chunfu Wang; Rhea Sumpter; Masanori Ikeda; Stanley M Lemon; Michael Gale
Journal:  Science       Date:  2003-04-17       Impact factor: 47.728

6.  Does Toll-like receptor 3 play a biological role in virus infections?

Authors:  Kurt H Edelmann; Sarah Richardson-Burns; Lena Alexopoulou; Kenneth L Tyler; Richard A Flavell; Michael B A Oldstone
Journal:  Virology       Date:  2004-05-01       Impact factor: 3.616

7.  The N- and C-terminal domains of the NS1 protein of influenza B virus can independently inhibit IRF-3 and beta interferon promoter activation.

Authors:  Nicola R Donelan; Bianca Dauber; Xiuyan Wang; Christopher F Basler; Thorsten Wolff; Adolfo García-Sastre
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

8.  The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses.

Authors:  Mitsutoshi Yoneyama; Mika Kikuchi; Takashi Natsukawa; Noriaki Shinobu; Tadaatsu Imaizumi; Makoto Miyagishi; Kazunari Taira; Shizuo Akira; Takashi Fujita
Journal:  Nat Immunol       Date:  2004-06-20       Impact factor: 25.606

9.  The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3.

Authors:  Christopher F Basler; Andrea Mikulasova; Luis Martinez-Sobrido; Jason Paragas; Elke Mühlberger; Mike Bray; Hans-Dieter Klenk; Peter Palese; Adolfo García-Sastre
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

10.  Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist activity for the NDV V protein and the Nipah virus V, W, and C proteins.

Authors:  Man-Seong Park; Megan L Shaw; Jorge Muñoz-Jordan; Jerome F Cros; Takaaki Nakaya; Nicole Bouvier; Peter Palese; Adolfo García-Sastre; Christopher F Basler
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

View more
  77 in total

1.  Crystal structure of the Lassa virus nucleoprotein-RNA complex reveals a gating mechanism for RNA binding.

Authors:  Kathryn M Hastie; Tong Liu; Sheng Li; Liam B King; Nhi Ngo; Michelle A Zandonatti; Virgil L Woods; Juan Carlos de la Torre; Erica Ollmann Saphire
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-14       Impact factor: 11.205

2.  Induction and inhibition of type I interferon responses by distinct components of lymphocytic choriomeningitis virus.

Authors:  Shenghua Zhou; Anna M Cerny; An Zacharia; Katherine A Fitzgerald; Evelyn A Kurt-Jones; Robert W Finberg
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

3.  Interplay of PA-X and NS1 Proteins in Replication and Pathogenesis of a Temperature-Sensitive 2009 Pandemic H1N1 Influenza A Virus.

Authors:  Aitor Nogales; Laura Rodriguez; Marta L DeDiego; David J Topham; Luis Martínez-Sobrido
Journal:  J Virol       Date:  2017-08-10       Impact factor: 5.103

4.  Lymphocytic Choriomeningitis Virus Differentially Affects the Virus-Induced Type I Interferon Response and Mitochondrial Apoptosis Mediated by RIG-I/MAVS.

Authors:  Christelle Pythoud; Sylvia Rothenberger; Luis Martínez-Sobrido; Juan Carlos de la Torre; Stefan Kunz
Journal:  J Virol       Date:  2015-04-01       Impact factor: 5.103

5.  Arenavirus nucleoprotein targets interferon regulatory factor-activating kinase IKKε.

Authors:  Christelle Pythoud; W W Shanaka I Rodrigo; Giulia Pasqual; Sylvia Rothenberger; Luis Martínez-Sobrido; Juan Carlos de la Torre; Stefan Kunz
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

6.  Genetic variation in vitro and in vivo of an attenuated Lassa vaccine candidate.

Authors:  Juan C Zapata; Marco Goicochea; Yuka Nadai; Lindsay M Eyzaguirre; Jean K Carr; Luke J Tallon; Lisa Sadzewicz; Garry Myers; Claire M Fraser; Qi Su; Mahmoud Djavani; Igor S Lukashevich; Maria S Salvato
Journal:  J Virol       Date:  2013-12-11       Impact factor: 5.103

7.  Lassa virus nucleoprotein mutants generated by reverse genetics induce a robust type I interferon response in human dendritic cells and macrophages.

Authors:  Xavier Carnec; Sylvain Baize; Stéphanie Reynard; Laure Diancourt; Valérie Caro; Noel Tordo; Michèle Bouloy
Journal:  J Virol       Date:  2011-08-31       Impact factor: 5.103

8.  Structure of the Lassa virus nucleoprotein reveals a dsRNA-specific 3' to 5' exonuclease activity essential for immune suppression.

Authors:  Kathryn M Hastie; Christopher R Kimberlin; Michelle A Zandonatti; Ian J MacRae; Erica Ollmann Saphire
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-24       Impact factor: 11.205

9.  Genomic profiling of host responses to Lassa virus: therapeutic potential from primate to man.

Authors:  Juan C Zapata; Maria S Salvato
Journal:  Future Virol       Date:  2015-03-13       Impact factor: 1.831

10.  Identification of critical amino acids within the nucleoprotein of Tacaribe virus important for anti-interferon activity.

Authors:  Brooke Harmon; Carol Kozina; Dianna Maar; Timothy S Carpenter; Catherine S Branda; Oscar A Negrete; Bryan D Carson
Journal:  J Biol Chem       Date:  2013-02-04       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.